Evaluation of the relationship between concentration of endothelin-1 and magnesium in the blood and the severity of ischemic heart disease

Abstract

Aim. To study the relationship between concentrations of endothelin-1 and magnesium in blood depending on functional class and old myocardial infarction in patients with stable angina.

Methods. The study included 58 patients with ischemic heart disease, II and III functional class stable angina. 19 of these patients suffered a myocardial infarction in the past. The control group consisted of 25 healthy volunteers. Endothelin-1 level in blood serum was determined by enzyme immunoassay, the concentration of magnesium by colorimetric method.

Results.Endothelin-1 level in the general group of patients with stable angina was 1.28±0.23 fmol/ml and was significantly higher than that of control group (0.52±0.13 fmol/ml, p

Conclusion. In patients with II-III functional class stable angina statistically significant increase in level of endothelin-1 and a decrease in the concentration of magnesium in blood serum compared with the control group was revealed; a negative correlation between endothelin-1 and magnesium levels in the blood, which is characterized by increasing the degree of correlation depending on the severity of the ischemic heart disease clinical form was established.

Keywords

stable angina / endothelial dysfunction / endothelin-1 / magnesium

References

[1] Бабушкина Н.В., Сергеева А.С., Пивоваров Ю.Н. и др. Структурные и функциональные особенности сосудистого эндотелия. Кардиология. 2015; (2): 82-86.

[2] Гомазков О.А. Эндотелин в кардиологии: молекулярные, физиологические и патологические аспекты (обзор). Кардиология. 2001; (2): 50-58.

[3] Спасов А.А., Харитонова М.В., Иежица Н.Н. и др. Функциональные резервы сердца в условиях алиментарного дефицита магния. Кардиология. 2012; (10): 39-44.

[4] Соколов Е.И., Гришина Т.Н., Штин С.Р. Влияние фактора Виллебранда и эндотелина-1 на формирование тромботического статуса при ишемической болезни сердца. Кардиология. 2013; (3): 25-30.

[5] Шилов А.М., Святов И.С., Кравченко В.В. и др. Применение препаратов магния для профилактики нарушений ритма сердца у больных острым инфарктом миокарда. Рос. кардиол. ж. 2002; (1): 16-19.

[6] Balliqand J.L. New mechanisms of LDL - cholesterol induced endothelial dysfunction; correction by statins. Bull. Mem. Belq. 2002; 157: 427-431.

[7] Berthon N., Laurant P., Hayoz D. et al. Magnesium supplementation and deoxycorticosterone acetate - salt hypertension: effect on arterial mechanical properties and activity of endothelin-1. Can. J. Physiol. Pharmacol. 2002; 80: 553-561. http://dx.doi.org/10.1139/y02-082

[8] Daviqnon J., Ganz P. Role of endotyelial dysfunction in atherosclerosis. Circulation. 2004; 109 (III): 27-32.

[9] Khan I.A. Role endothelin-1 in acute myocardial infarction. Chest. 2005; 127: 1474-1476. http://dx.doi.org/10.1378/chest.127.5.1474

[10] Kupetsky-Rincon E.A., Uitto J. Magnesium: novel applications in cardiovascular disease - a review of the literature. Ann. Nutr. Metab. 2012; 61: 102-110. http://dx.doi.org/10.1159/000339380

[11] Laurant P., Kantelip J.P., Berthelot A. Dietary magnesium supplementation modifies blood pressure and cardiovascular function in mineralocorticoid - salt hypertensive rats but not in normotensive rats. S. Natur. 1995; 125: 830-841.

[12] Negrusz-Kawchka M. The role of endothelins in human cardiovascular disease. Pol. Merkuriusz. Lek. 2001; 11: 444-446.

[13] Omland T., Lie R.T., Aarsland T., Dickstein K. Plaimaendothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation. 1994; 89: 1573-1579. http://dx.doi.org/10.1161/01.CIR.89.4.1573

[14] Rosanoff A., Plesser M.R. Oral magnesium supplements decrease high blood pressure (SBP 3155 mm Hg) in hypertensive subjects on anti-hypertensive medications: a targeted meta-analys. Magnes. Res. 2013; 26: 93-99.

[15] Rokan R., Hofmann P., van Duvillard S.P. et al. Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients. Br. J. Sports Med. 2006; 40 (9): 773-778. http://dx.doi.org/10.1136/bjsm.2006.027250

[16] Shechter M., Sharir M., Labrador M.S. et al. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation. 2000; 102: 2353-2358. http://dx.doi.org/10.1161/01.CIR.102.19.2353

[17] Schuitemaker G.E., van der Pol G.A., Aretz C.P., Dinant G.J. A placebo-controlled, double-blind, randomized trial of magnesium-pyridoxal-5’-phosphate-glutamate for hypercholoterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting. Eur. J. Clin. Pharmacol. 2001; 56: 857-863. http://dx.doi.org/10.1007/s002280000247

[18] Ueshima K. Magnesium and ishemic heart disease: a review of epidemiological experimental and clinical evidences. Magnes. Res. 2005; 18: 275-284.

[19] Zolk O., Qattek J., Sitzler G. et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation. 1999; 99: 2118-2123. http://dx.doi.org/10.1161/01.CIR.99.16.2118

RIGHTS & PERMISSIONS

Abdullayev R.F., Bakhshaliev A.B., Gulieva A.D., Huseynzade R.R.